Metagenomi Therapeutics Inc

metagenomi.co

What Do They Do?

Develops genome-editing genetic medicines for patients, including a hemophilia A program and partnered treatments for cardiometabolic diseases.

How Do They Make Money?

Receives upfront payments, research cost reimbursements, and milestone payments under license and research agreements; it may also receive royalties and commercial sales milestone payments if partnered products reach sales targets.

FY2025 revenue

Who Are Their Customers?

Its collaboration and license agreements are with pharmaceutical partners, including Ionis; all reported revenue relates to contracts with customers located in the U.S.

Do Revenues Turn Into Profits?

No. It lost $87.9M in FY2025.

Operating income, FY2025

−381% of revenue

▲ +8% (Loss) vs FY2024 (−$88.9M, −170%)

Net income, FY2025

−349% of revenue

▲ +13% (Loss) vs FY2024 (−$78.1M, −149%)

Free cash flow, FY2025

−355% of revenue

▼ −20% (Loss) vs FY2024 (−$112.2M, −215%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Net income: ▲ +38% (Loss); vs −$19.9M in Q2 FY2025

Aug 10, 2026 Metagenomi stayed on schedule for its MGX-001 clinical-trial application The planned global clinical program targets hemophilia A, with trials expected to begin in 2027 subject to regulatory clearance.

Who Do They Compete With?

Competes with Caribou Biosciences, Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics, Precision BioSciences, Cellectis, Beam Therapeutics, Verve Therapeutics, Eli Lilly and, Prime Medicine, Tessera Therapeutics, nChroma Bio, Tune Therapeutics, Arbor Biotechnologies, Scribe Therapeutics, Mammoth Biosciences, Recode Therapeutics, and Generation Bio

Comments